During a two year prospective study onpatients from department's hospitals and centralized by the pneumology department Nantes CH,all respiratory clinical samples will be cultivated for Aspergillus isolation (2900Aspergillusisolates) as standard care. The azole susceptibility pattern of isolates will be determined to itraconazole, voriconazole by subculture on azole- enriched medium at 35°c as primary screen and resistance confirmed by EUCAST Reference metho.In parallel, the relevance of detecting resistance (TR34 and TR46) directly in culture-negative BAL respiratory samples by a qPCR method will be studied in an attempt to reach a greater exhaustiveness of the resistance phenomeno. In case of azole-resistant isolate,patient data such as the underlying disease,date and site of Aspergillus isolation,disease classification,previous azole drug exposure,and home and work geographic allocation,occupation of the patient will be collecte. For all other aspergillus occurrences, underlying disease, previous azole drug exposure,home and work location of the patient will be collected in an attempt to identify risk factor.
Study Type
OBSERVATIONAL
Enrollment
1,000
No intervention excepted data collection
Environmental risk factors
Identify the "macro" environmental risk factors for acquiring azole-resistant aspergillus.
Time frame: 24 months
Describe the management and evolution of resistant
Clinical information from each additional patient visit and presence or absence of resistant Aspergillus in home samples.
Time frame: 48 months
Risk factors
Identify individual risk factors linked to the immediate environment in the patient's home, drug management, between cases and matched controls, etc..
Time frame: 48 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.